Skip to main content
Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc. — Investor Relations & Filings

Ticker · CLRB ISIN · US15117F8077 LEI · 5493000NFZCRG7BYQV93 US Manufacturing
Open in API
Filings indexed 1,033 across all filing types
Latest filing 2012-06-20 Regulatory Filings
Country US United States of America
Listing US CLRB

About Cellectar Biosciences, Inc.

https://www.cellectar.com/

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted cancer treatments. The company's core technology is a proprietary Phospholipid Drug Conjugate (PDC) platform that selectively delivers therapeutic payloads, such as radioisotopes and cytotoxins, to cancer cells by targeting lipid rafts in their plasma membranes. This approach is designed to maximize antitumor activity while minimizing off-target effects on healthy tissue. Cellectar's lead product candidate is iopofosine I 131, a first-in-class PDC that delivers the radioisotope iodine-131. It is being developed for the treatment of hematologic malignancies and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Waldenstrom's Macroglobulinemia.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text specifically mentions that the filing includes a press release about initial imaging results in a clinical trial. There are no financial statements or detailed financial data included, and the document is relatively short (2897 characters). It is primarily an announcement of a press release rather than a full financial report or detailed disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2012-06-20 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 14, 2012. It announces the closing of a $5.4 million registered public offering of units consisting of common stock and warrants, and the dismissal of a securities class action lawsuit. The document references a press release as Exhibit 99.1. The content focuses on a financing event and legal update rather than full financial statements or detailed financial results. The length is 2944 characters, which is relatively short and consistent with an announcement rather than a full report. Given the focus on financing and the public offering, the document fits best under Capital/Financing Update (CAP).
2012-06-14 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 7, 2012, by Novelos Therapeutics, Inc. The content describes the entry into a material definitive agreement involving the sale of common stock and warrants, with details on the securities purchase agreement and proceeds. It also references a press release about the public offering. The primary focus is on a financing transaction and capital raising activity. There are no financial statements or comprehensive financial data presented, only a description of the financing event and related agreements. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes.
2012-06-11 English
RULE 424(B)(1)
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(1) related to an offering of units consisting of common stock and warrants by Novelos Therapeutics, Inc. It includes detailed information about the offering, risk factors, use of proceeds, capitalization, management discussion and analysis, business overview, litigation, and financial statements. The document is clearly a registration/prospectus filing related to capital raising and securities offering, which fits the category of Capital/Financing Update filings. It is not an annual report, earnings release, or other financial report, but rather a detailed offering document for securities issuance.
2012-06-08 English
Regulatory Filings 2012
Regulatory Filings
2012-06-08 English
Regulatory Filings 2012
Regulatory Filings Classification · 95% confidence The document is a letter from the President and CEO of Novelos Therapeutics, Inc. to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-1. It references Rule 461(a) under the Securities Act of 1933 and the filing number 333-180631. The content is a formal request related to a registration statement effectiveness, not the registration statement itself or any financial report. The document length is short (1739 characters) and it is clearly an announcement/request related to a regulatory filing. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory communication that does not fit other specific categories.
2012-06-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.